Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more
Photocure ASA (PHCUF) - Total Liabilities
Latest total liabilities as of September 2025: $209.21 Million USD
Based on the latest financial reports, Photocure ASA (PHCUF) has total liabilities worth $209.21 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Photocure ASA - Total Liabilities Trend (2002–2024)
This chart illustrates how Photocure ASA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Photocure ASA Competitors by Total Liabilities
The table below lists competitors of Photocure ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Summit Bank Group Inc
PINK:SBKO
|
USA | $1.13 Billion |
|
EASY BIOInc
KQ:353810
|
Korea | ₩225.48 Billion |
|
Galaxy Software Services Corporation
TWO:6752
|
Taiwan | NT$1.28 Billion |
|
Discovery Holdings Ltd
JSE:DSY
|
South Africa | ZAC261.75 Billion |
|
Sanderson Design Group plc
PINK:WKGBF
|
USA | $28.47 Million |
|
Semperit Aktiengesellschaft Holding
PINK:SEIGF
|
USA | $454.60 Million |
|
IndoStar Capital Finance Limited
NSE:INDOSTAR
|
India | ₹55.85 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Photocure ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Photocure ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Photocure ASA (2002–2024)
The table below shows the annual total liabilities of Photocure ASA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $237.37 Million | +3.60% |
| 2023-12-31 | $229.12 Million | -10.60% |
| 2022-12-31 | $256.30 Million | -10.70% |
| 2021-12-31 | $287.01 Million | +7.13% |
| 2020-12-31 | $267.92 Million | +449.43% |
| 2019-12-31 | $48.76 Million | -11.10% |
| 2018-12-31 | $54.85 Million | +21.84% |
| 2017-12-31 | $45.02 Million | +32.77% |
| 2016-12-31 | $33.91 Million | -10.76% |
| 2015-12-31 | $38.00 Million | +24.50% |
| 2014-12-31 | $30.52 Million | -6.39% |
| 2013-12-31 | $32.60 Million | -38.15% |
| 2012-12-31 | $52.71 Million | -24.53% |
| 2011-12-31 | $69.85 Million | +27.02% |
| 2010-12-31 | $54.99 Million | +33.86% |
| 2009-12-31 | $41.08 Million | +7.67% |
| 2008-12-31 | $38.15 Million | -7.85% |
| 2007-12-31 | $41.40 Million | -14.62% |
| 2006-12-31 | $48.49 Million | -15.29% |
| 2005-12-31 | $57.24 Million | -35.06% |
| 2004-12-31 | $88.14 Million | -13.16% |
| 2003-12-31 | $101.50 Million | -23.11% |
| 2002-12-31 | $132.01 Million | -- |